Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript [Seeking Alpha]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Seeking Alpha
Company Participants Mani Mohindru Roger Sidhu - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen, Research Division Maurice Raycroft - Jefferies LLC, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Gum-Ming Lowe - Craig-Hallum Capital Group LLC, Research Division Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Christopher Liu - Lucid Capital Markets, LLC, Research Division John Vandermosten - Zacks Small-Cap Research Presentation Operator Welcome to the Cardiff Oncology Onvansertib Data Update Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to Candice Masse of Astr Partners. Please go ahead. Mani Mohindru Thank you, operator. This is Mani Mohindru from Cardiff. Given the technical difficulties, I'm going to take over. Joining the ca
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology (NASDAQ:CRDF) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRCGlobeNewswire
- Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical DevelopmentGlobeNewswire
- Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm [Seeking Alpha]Seeking Alpha
- Cardiff Oncology (NASDAQ:CRDF) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $12.00 price target on the stock.MarketBeat
CRDF
Earnings
- 11/6/25 - Beat
CRDF
Sec Filings
- 1/27/26 - Form 8-K
- 11/6/25 - Form 8-K
- 11/6/25 - Form 10-Q
- CRDF's page on the SEC website